Author

A. Sowalsky

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:statistical model· 2 Assay:ATAC-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. A. Hamid· 1 shared A. D. Choudhury· 1 shared A. Mitrofanova· 1 shared A. S. Kibel· 1 shared A. V. Sheahan· 1 shared A. Varkaris· 1 shared B. Ersoy-Fazlioglu· 1 shared B. M. Olson· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Hamid

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Increased chromatin accessibility mediated by nuclear factor I drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancer

L. Poluben, M. Nouri, J. Liang, A. Varkaris, B. Ersoy-Fazlioglu, O. Voznesensky, I. Lee, X. Qiu, L. Cato, J.-H. Seo, M. Freedman, A. Sowalsky, N. Lack, E. Corey, P. Nelson, , S. Balk

This study shows that ARv7 drives AR activity in castration-resistant prostate cancer through increased chromatin accessibility mediated by NFI factors.

bioRxiv · Jan 10, 2024 · PreprintCancer Biology

Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate Cancer

A. V. Sheahan, K. L. Morel, D. L. Burkhart, S. C. Baca, D. P. Labbe, K. Roehle, M. Heckler, C. Calagua, H. Ye, P. Galbo, S. Panja, A. Mitrofanova, A. A. Hamid, A. S. Kibel, A. D. Choudhury, , L. Ellis

This study shows that inhibiting EZH2 enhances the effectiveness of PD-1 checkpoint inhibitors in prostate cancer by increasing PD-L1 expression and immune cell infiltration.

bioRxiv · Aug 8, 2019 · PreprintCancer Biology